Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001213900-25-004221
Filing Date
2025-01-16
Accepted
2025-01-16 16:30:15
Documents
18
Period of Report
2025-01-10

Document Format Files

Seq Description Document Type Size
1 PRELIMINARY PROXY STATEMENT ea0227318-pre14a_citius.htm   iXBRL PRE 14A 516098
2 GRAPHIC image_001.jpg GRAPHIC 86775
3 GRAPHIC image_002.jpg GRAPHIC 369291
4 GRAPHIC image_003.jpg GRAPHIC 640951
  Complete submission text file 0001213900-25-004221.txt   4155633

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ctxr-20250109.xsd EX-101.SCH 11027
6 XBRL DEFINITION FILE ctxr-20250109_def.xml EX-101.DEF 5386
7 XBRL LABEL FILE ctxr-20250109_lab.xml EX-101.LAB 36765
8 XBRL PRESENTATION FILE ctxr-20250109_pre.xml EX-101.PRE 7756
20 EXTRACTED XBRL INSTANCE DOCUMENT ea0227318-pre14a_citius_htm.xml XML 206104
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: PRE 14A | Act: 34 | File No.: 001-38174 | Film No.: 25535996
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)